0000899243-23-002434.txt : 20230123
0000899243-23-002434.hdr.sgml : 20230123
20230123183553
ACCESSION NUMBER: 0000899243-23-002434
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230119
FILED AS OF DATE: 20230123
DATE AS OF CHANGE: 20230123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: de los Pinos Elisabet
CENTRAL INDEX KEY: 0001889633
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40971
FILM NUMBER: 23545514
MAIL ADDRESS:
STREET 1: C/O AURA BIOSCIENCES, INC.
STREET 2: 85 BOLTON STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aura Biosciences, Inc.
CENTRAL INDEX KEY: 0001501796
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 320271970
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 80 GUEST STREET
CITY: BOSTON
STATE: MA
ZIP: 01235
BUSINESS PHONE: (617)500-8864
MAIL ADDRESS:
STREET 1: 80 GUEST STREET
CITY: BOSTON
STATE: MA
ZIP: 01235
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-19
0
0001501796
Aura Biosciences, Inc.
AURA
0001889633
de los Pinos Elisabet
C/O AURA BIOSCIENCES, INC.
80 GUEST STREET
BOSTON
MA
01235
1
1
0
0
See Remarks
Common Stock
2023-01-19
4
A
0
121875
0.00
A
190526
D
Common Stock
131412
I
By EdIP Revocable Trust
Stock Option (Right to Buy)
10.18
2023-01-19
4
A
0
187500
A
2033-01-18
Common Stock
187500
187500
D
These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant.
The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.
The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments.
President and Chief Executive Officer
/s/ Julie Feder, as Attorney-in-Fact
2023-01-23